- Conditions
- Nasal Allergies, Allergies
- Interventions
- AL-53817 nasal spray solution, Vehicle nasal spray
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intraabdominal Infections
- Interventions
- Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- San Diego, California • Springfield, Massachusetts
- Conditions
- Autism Spectrum Disorder
- Interventions
- N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Mild Cognitive Impairment (MCI), Cognition, Brain Aging, Microbiome Dysbiosis, Leaky Gut Syndrome, Gut Inflammation, Inflammaging
- Interventions
- LpD3.5, Placebo
- Dietary Supplement
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- NIDDM, Obesity
- Interventions
- Metformin Extended Release (ER) Oral Tablet, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Opioid Use Disorder
- Interventions
- [11C]-PHNO, Calcitriol, Placebo Control, PET Scan
- Drug · Dietary Supplement · Other + 1 more
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Atrophy of Vagina, Menopause, Dyspareunia (Female)
- Interventions
- Vagifem, Replens, Placebo tablet, Placebo gel
- Drug · Device · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 45 Years to 70 Years · Female only
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Proteinuria, Idiopathic Membranous Nephropathy
- Interventions
- Repository Corticotropin Injection, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 14
- States / cities
- Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Exudative Age-Related Macular Degeneration
- Interventions
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Drug
- Lead sponsor
- Alcon, a Novartis Company
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Back Pain, Depressive Symptoms
- Interventions
- CBD, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Eyes Dry Chronic
- Interventions
- ESBA105 ophthalmic solution, ESBA105 vehicle
- Biological · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
- Interventions
- Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Schizophrenia
- Interventions
- N-acetylcysteine (NAC), Inactive placebo capsule
- Drug
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Kidney Diseases
- Interventions
- Pioglitazone, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas at Arlington
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Arlington, Texas • Dallas, Texas
- Conditions
- Cognitive, Mood and Cognitive Performance, Sleep Deprivation, Executive Function (Cognition), Fatigue
- Interventions
- Alpha Brain proprietary cognitive dietary supplement, Alpha Brain 2.0 proprietary cognitive dietary supplement, Controlled Placebo
- Dietary Supplement
- Lead sponsor
- Applied Science & Performance Institute
- Industry
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Deferasirox, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 11
- States / cities
- Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more
- Conditions
- Vaccination, Skin Absorption
- Interventions
- Microneedle Formulation 1, Microneedle Formulation 2
- Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Weeks to 24 Months
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Dry Eye Disease
- Interventions
- Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas